Article
Construction of Probiotic Escherichia coli Nissle 1917 as a Next- Generation Expression Platform and Its Application in Therapeutic Protein Production
2025-09-19
Abstract excerpt
<title>Abstract</title> <p> Biologics produced in <italic>Escherichia coli</italic> BL21(DE3) require rigorous removal of lipopolysaccharide (LPS), also termed endotoxin, as its presence can elicit severe immune responses and life threatening complications in humans. <italic>Escherichia coli</italic> Nissle 1917 (EcN) is a clinically approved probiotic with unique biosafety characteristics due to its LPS-def...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b55845cc-b140-5a9e-a7eb-5e6bc86ff923
- DOI
- 10.21203/rs.3.rs-7512809/v1
